Healthcare / BiotechnologyTokyo
$425.00
+8.00 (+1.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-223.6M · quality 43.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.1%
FCF CAGR
—
FCF margin
-362.6%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $91.1M · net income $-425.7M · FCF $-330.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $91.1M | $91.1M | $194.6M | $360.4M | $178.8M |
| Net Income | $-425.7M | $-425.7M | $-236.4M | $33.0M | $-141.4M |
| EBITDA | $-380.8M | $-380.8M | $-197.3M | $64.6M | $-108.4M |
| EPS | — | — | -37.11 | 6.01 | -25.70 |
| Operating Margin | -435.3% | -435.3% | -109.4% | 10.4% | -77.7% |
| Net Margin | -467.1% | -467.1% | -121.5% | 9.2% | -79.1% |
| Balance Sheet | |||||
| Current Ratio | 18.46 | 18.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-330.5M | $-330.5M | $-223.6M | $66.7M | $-204.3M |
| Returns | |||||
| ROE | -23.9% | -23.9% | -10.7% | 2.1% | -9.2% |
| Valuation | |||||
| P/B | 1.55 | 1.55 | 2.54 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -53.2% | -53.2% | -46.0% | 101.5% | — |
| EPS Growth | — | — | -717.5% | 123.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-37.11 → n/d
Residual
-37.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.